Trial reportPediatric blood & cancer2015
Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.
Trial report in Pediatric blood & cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- All-site radiotherapy for metastatic ewing's sarcoma: a short-term analysis of feasibility, response, and safety.Clinical & experimental metastasis · 2026Article
- TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma.Cancer research communications · 2025Article
- UK guidelines for the management of bone sarcomas.British journal of cancer · 2025Review
- Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan.Cancer medicine · 2024Observational
- Review
- Fifty years of bone tumors.Journal of surgical oncology · 2022Article
- Clinical outcomes and efficacy of stereotactic body radiation therapy in children, adolescents, and young adults with metastatic solid tumors.The British journal of radiology · 2022Article
- The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone.Journal of bone oncology · 2021Article
- Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives.Journal of clinical medicine · 2021Review
- A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
- A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.Journal of orthopaedic surgery and research · 2020Article
- Effects of different treatments and other factors on the prognosis of patients with ewing sarcoma.Translational cancer research · 2020Article
- Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities.International journal of radiation oncology, biology, physics · 2018Article
- Central nervous system relapse of rhabdomyosarcoma.Pediatric blood & cancer · 2018Article
- Management of Ewing sarcoma family of tumors: Current scenario and unmet need.World journal of orthopedics · 2016Review
- Radiotherapy is Important for Local Control at Primary and Metastatic Sites in Pediatric Rhabdomyosarcoma.Cureus · 2015Article
- Ewing's Sarcoma Multifocal Metastases to Temporal and Occipital Bone: A Rare Presentation.Journal of clinical and diagnostic research : JCDR · 2015Article
- Metastatic Ewing's Sarcoma: Revisiting the "Evidence on the Fence".Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric OncologyReview
- Advances in Radiation Therapy for Primary Bone Malignancies.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe role, optimal dose, and efficacy of radiotherapy (RT) for the treatment of bone metastases in rhabdomyosarcoma (RMS) and Ewing sarcoma (ES) are unclear. PROCEDURE: All patients with ES or RMS who received RT for bone metastases with curative intent during frontline therapy at Memorial Sloan Kettering Cancer Center (MSKCC) between 1995 and 2013 were reviewed. Among the 30 patients (8 RMS and 22 ES), 49 bone metastases were irradiated.
resultsMedian biologically effective dose (BED) was 42.4 Gy (range, 34.9-59.7) for RMS and 50.7 Gy (range, 31.3-65.8) for ES. Tumor recurrence occurred in six of 49 irradiated bone metastases. Cumulative incidence of local failure at a treated metastatic site was 6.6% at 1 year and 9.0% at 3 years. Dose, fractionation, and RT technique did not impact local control at an irradiated site. The presence of >5 bone metastases was associated with worse local control at an irradiated site (P = 0.07). The 3-year EFS was 33% in RMS and 16% in ES.
conclusionsRT appears to be an effective modality of local control for bone metastases in ES and RMS. Local control at sites of metastatic bone irradiation is similar to local control at the primary site after definitive RT. Doses in the biologic range prescribed for the definitive treatment of primary disease should be used for metastatic sites of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.